102 related articles for article (PubMed ID: 1493949)
1. Peptidyl antithrombogenic agents for extracorporeal blood circulation.
Ito S; Matsuda T; Takemoto Y; Yamamoto K; Kishimoto T; Maekawa M
Int J Artif Organs; 1992 Dec; 15(12):737-45. PubMed ID: 1493949
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel potent peptidyl platelet preserving agent: molecular design and biologic activity.
Ozeki E; Matsuda T
ASAIO Trans; 1990; 36(3):M562-4. PubMed ID: 2252751
[TBL] [Abstract][Full Text] [Related]
3. The peptide Glu-His-Ile-Pro-Ala binds fibrinogen and inhibits platelet aggregation and adhesion to fibrinogen and vitronectin.
Gartner TK; Taylor DB
Proc Soc Exp Biol Med; 1991 Oct; 198(1):649-55. PubMed ID: 1716370
[TBL] [Abstract][Full Text] [Related]
4. A modified Arg-Asp-Val (RDV) peptide derived during the synthesis of Arg-Glu-Asp-Val (REDV), a tetrapeptide derived from an alternatively spliced site in fibronectin, inhibits the binding of fibrinogen, fibronectin, von Willebrand factor and vitronectin to activated platelets.
Chen CS; Papayannopoulos IA; Timmons S; Chou SH; Thiagarajan P
Biochim Biophys Acta; 1991 Oct; 1075(3):237-47. PubMed ID: 1720019
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp.
Varon D; Lider O; Dardik R; Shenkman B; Alon R; Hershkoviz R; Kapustina G; Savion N; Martinowitz U; Greenspoon N
Thromb Haemost; 1993 Dec; 70(6):1030-6. PubMed ID: 8165596
[TBL] [Abstract][Full Text] [Related]
6. New RGD analogue inhibits human platelet adhesion and aggregation and eliminates platelet deposition on canine vascular grafts.
Rubin BG; McGraw DJ; Sicard GA; Santoro SA
J Vasc Surg; 1992 Apr; 15(4):683-91; discussion 691-2. PubMed ID: 1560559
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins. RGD-containing peptides from viper venoms.
Musial J; Niewiarowski S; Rucinski B; Stewart GJ; Cook JJ; Williams JA; Edmunds LH
Circulation; 1990 Jul; 82(1):261-73. PubMed ID: 2364514
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of an Asp-Ser sequence to form an RGDS-like motif in hirutonin: the effect on in vitro platelet function.
van Wyk V; Leblond L; Winocour PD; Devine DV; Gyongyossy-Issa MI
Thromb Res; 2000 Aug; 99(4):343-52. PubMed ID: 10963785
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of platelet adhesion to fibrin(ogen) in flowing whole blood by Arg-Gly-Asp and fibrinogen gamma-chain carboxy terminal peptides.
Hantgan RR; Endenburg SC; Cavero I; Marguerie G; Uzan A; Sixma JJ; de Groot PG
Thromb Haemost; 1992 Dec; 68(6):694-700. PubMed ID: 1287884
[TBL] [Abstract][Full Text] [Related]
10. A synthetic tetrapeptide as a novel platelet-preserving agent during cardiopulmonary bypass.
Tatsumi E; Matsuda T; Takano H; Taenaka Y; Noda H; Kinoshita M; Sekii H; Yagura A; Takaichi S; Akutsu T
ASAIO Trans; 1988; 34(3):813-6. PubMed ID: 3196604
[TBL] [Abstract][Full Text] [Related]
11. Potent inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Asp-carboxylate of RGDX mimetics and the platelet GP IIb-IIIa receptor.
Zablocki JA; Miyano M; Rao SN; Panzer-Knodle S; Nicholson N; Feigen L
J Med Chem; 1992 Dec; 35(26):4914-7. PubMed ID: 1479591
[No Abstract] [Full Text] [Related]
12. Anti-thrombotic activity of RG13965, a novel platelet fibrinogen receptor antagonist.
Bostwick JS; Kasiewski CJ; Chu V; Klein SI; Sabatino RD; Perrone MH; Dunwiddie CT; Cook JJ; Leadley RJ
Thromb Res; 1996 Jun; 82(6):495-507. PubMed ID: 8794522
[TBL] [Abstract][Full Text] [Related]
13. Aggregate formation is more strongly inhibited at high shear rates by dRGDW, a synthetic RGD-containing peptide.
Saelman EU; Hese KM; Nieuwenhuis HK; Uzan A; Cavero I; Marguerie G; Sixma JJ; de Groot PG
Arterioscler Thromb; 1993 Aug; 13(8):1164-70. PubMed ID: 8343490
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of platelet adhesion and aggregation by a defined region (Gly-486-Lys-502) of high molecular weight kininogen.
Chavakis T; Boeckel N; Santoso S; Voss R; Isordia-Salas I; Pixley RA; Morgenstern E; Colman RW; Preissner KT
J Biol Chem; 2002 Jun; 277(26):23157-64. PubMed ID: 11970955
[TBL] [Abstract][Full Text] [Related]
15. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model.
Cadroy Y; Houghten RA; Hanson SR
J Clin Invest; 1989 Sep; 84(3):939-44. PubMed ID: 2760221
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition of platelet aggregation by fibrinogen-related peptides.
Adelman B; Gennings C; Strony J; Hanners E
Circ Res; 1990 Oct; 67(4):941-7. PubMed ID: 2208617
[TBL] [Abstract][Full Text] [Related]
17. [Anti-adhesive and anti-thrombotic effects of integrin-inhibiting tripeptides (Arg-Gly-Asp)].
Udvardy M
Orv Hetil; 1995 Oct; 136(40):2155-9. PubMed ID: 7566948
[TBL] [Abstract][Full Text] [Related]
18. Chimeric derivative of fibrolase, a fibrinolytic enzyme from southern copperhead venom, possesses inhibitory activity on platelet aggregation.
Swenson S; Bush LR; Markland FS
Arch Biochem Biophys; 2000 Dec; 384(2):227-37. PubMed ID: 11368309
[TBL] [Abstract][Full Text] [Related]
19. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
[TBL] [Abstract][Full Text] [Related]
20. Arginine-glycine-aspartic acid- and fibrinogen gamma-chain carboxyterminal peptides inhibit platelet adherence to arterial subendothelium at high wall shear rates. An effect dissociable from interference with adhesive protein binding.
Lawrence JB; Kramer WS; McKeown LP; Williams SB; Gralnick HR
J Clin Invest; 1990 Nov; 86(5):1715-22. PubMed ID: 2243140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
